{ "story_id": "8ab85421d9e694ca60182c2ceabf0a35", "desk": "drm3", "revision": 1, "published_at": "2026-09-02T10:39:57.000Z", "content_hash": "d02884b525821b419fb4858759f93b8839dabeeade30ee54757b0ef965157f65", "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs", "basis": { "headline": "94% of U.S. Adults Concerned About Frequency of Food Recalls", "dek": "A new survey reveals 94% of U.S. adults worry about how often food is recalled.", "prose": "A survey commissioned by GS1 US found that 94 percent of U.S. adults were concerned about the frequency of food recalls in 2026, up from 93 percent in 2025. [^1]\n\nOptiscan Imaging Ltd, a company listed on the Australian Securities Exchange under the ticker ASX:OIL, has initiated a new clinical study. [^2]\n\nUBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved. [^3]\n\n67 percent of survey respondents said they had avoided an entire food product category following a recall, up from 60 percent in 2025. [^4]\n\nThe survey indicated that 80 percent of respondents believed food recalls were effective in protecting public health and safety in 2026, down from 85 percent in 2025. [^5]\n\nOptiscan Imaging Ltd has partnered with the Mayo Clinic to conduct this clinical evaluation. [^6]\n\nThe results of this study are intended to support the company's future submissions to the US Food and Drug Administration (FDA). [^7]\n\nThe study is based in the United States and focuses on imaging for head and neck cancer. [^8]\n\nRemediation costs have amounted to almost 20% of the company's cumulative free cash flow since 2015, according to UBS. [^9]\n\nUBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030. [^10]\n\nUBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories. [^11]\n\n59 percent of respondents said they had discarded recalled food even when their state or region was not affected, compared with 57 percent in 2025. [^12]", "cited": "[{\"statement\":\"A survey commissioned by GS1 US found that 94 percent of U.S. adults were concerned about the frequency of food recalls in 2026, up from 93 percent in 2025.\",\"source\":\"food-safety.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"food-safety.com\"]},{\"statement\":\"Optiscan Imaging Ltd, a company listed on the Australian Securities Exchange under the ticker ASX:OIL, has initiated a new clinical study.\",\"source\":\"South Florida Reporter\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T12:07:00.000Z\",\"publisher_count\":1,\"sources\":[\"South Florida Reporter\"]},{\"statement\":\"UBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:39:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"67 percent of survey respondents said they had avoided an entire food product category following a recall, up from 60 percent in 2025.\",\"source\":\"food-safety.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"food-safety.com\"]},{\"statement\":\"The survey indicated that 80 percent of respondents believed food recalls were effective in protecting public health and safety in 2026, down from 85 percent in 2025.\",\"source\":\"food-safety.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"food-safety.com\"]},{\"statement\":\"Optiscan Imaging Ltd has partnered with the Mayo Clinic to conduct this clinical evaluation.\",\"source\":\"South Florida Reporter\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T12:07:00.000Z\",\"publisher_count\":1,\"sources\":[\"South Florida Reporter\"]},{\"statement\":\"The results of this study are intended to support the company's future submissions to the US Food and Drug Administration (FDA).\",\"source\":\"South Florida Reporter\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T12:07:00.000Z\",\"publisher_count\":1,\"sources\":[\"South Florida Reporter\"]},{\"statement\":\"The study is based in the United States and focuses on imaging for head and neck cancer.\",\"source\":\"South Florida Reporter\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T12:07:00.000Z\",\"publisher_count\":1,\"sources\":[\"South Florida Reporter\"]},{\"statement\":\"Remediation costs have amounted to almost 20% of the company's cumulative free cash flow since 2015, according to UBS.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:39:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"UBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:39:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"UBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:39:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"59 percent of respondents said they had discarded recalled food even when their state or region was not affected, compared with 57 percent in 2025.\",\"source\":\"food-safety.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"food-safety.com\"]}]", "kind": "news" }, "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature", "receipt": null, "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record", "generation_chain": { "wire": { "stream": "fountain_news", "story_id": "dab2f987f2aa0d934a5badf4b38b2a15", "thread_id": "5af898eabb8ba9a4be05407fbdfa8302", "thread_label": "U.S. Food and Drug Administration", "novelty": "UPDATE", "content_hash": "f72350a043e237d9bfdfb4802a26e88ef81f7f13db4891ab98db8778aee653fc", "last_published_at": "2026-09-02T10:39:57.000Z", "read_receipt": { "slice_hash": "6f69d013059537a87af2b87c922b212011d4fe7ee12036f9066de5c4cc30281c", "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMDk6NTM6MDUuMDAwMDAwWiIsImlkIjoiNTA2NzViODllMmUyZDU3ZGJhMzQzOWRiYTFlYmRkYmYiLCJ2IjoiMSJ9", "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMTE6MDA6MjIuMDAwMDAwWiIsImlkIjoiM2RkNTFiYjNlY2NkMTFkMzc0ZmJjN2UyNWU0OTBhOWYiLCJ2IjoiMSJ9", "view": "v_fountain_news", "view_version": "1", "row_count": 100, "window_days": 3, "bytes_scanned": 12017721, "credits": 8, "price_per_100_rows": 8, "sig": "y-CC-1scxAEM_nQQodB8JAFq-dwPb14ApmlmnG93xGLLF_uL8rplYgVGN6oy6mZzw1MUve5kLVLnYlxMxRVBDA", "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE", "signer_path": "lakehouse/data-extract/v1", "alg": "Ed25519", "signed": true } }, "written_at": "2026-09-02T22:46:24.010Z" }, "cited_facts": [ { "statement": "A survey commissioned by GS1 US found that 94 percent of U.S. adults were concerned about the frequency of food recalls in 2026, up from 93 percent in 2025.", "source": "food-safety.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T11:00:00.000Z", "publisher_count": 1, "sources": [ "food-safety.com" ] }, { "statement": "Optiscan Imaging Ltd, a company listed on the Australian Securities Exchange under the ticker ASX:OIL, has initiated a new clinical study.", "source": "South Florida Reporter", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T12:07:00.000Z", "publisher_count": 1, "sources": [ "South Florida Reporter" ] }, { "statement": "UBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T10:39:57.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "67 percent of survey respondents said they had avoided an entire food product category following a recall, up from 60 percent in 2025.", "source": "food-safety.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T11:00:00.000Z", "publisher_count": 1, "sources": [ "food-safety.com" ] }, { "statement": "The survey indicated that 80 percent of respondents believed food recalls were effective in protecting public health and safety in 2026, down from 85 percent in 2025.", "source": "food-safety.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T11:00:00.000Z", "publisher_count": 1, "sources": [ "food-safety.com" ] }, { "statement": "Optiscan Imaging Ltd has partnered with the Mayo Clinic to conduct this clinical evaluation.", "source": "South Florida Reporter", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T12:07:00.000Z", "publisher_count": 1, "sources": [ "South Florida Reporter" ] }, { "statement": "The results of this study are intended to support the company's future submissions to the US Food and Drug Administration (FDA).", "source": "South Florida Reporter", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T12:07:00.000Z", "publisher_count": 1, "sources": [ "South Florida Reporter" ] }, { "statement": "The study is based in the United States and focuses on imaging for head and neck cancer.", "source": "South Florida Reporter", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T12:07:00.000Z", "publisher_count": 1, "sources": [ "South Florida Reporter" ] }, { "statement": "Remediation costs have amounted to almost 20% of the company's cumulative free cash flow since 2015, according to UBS.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T10:39:57.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "UBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T10:39:57.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "UBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T10:39:57.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "59 percent of respondents said they had discarded recalled food even when their state or region was not affected, compared with 57 percent in 2025.", "source": "food-safety.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T11:00:00.000Z", "publisher_count": 1, "sources": [ "food-safety.com" ] } ], "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true." }